Hepregen lands $500K SBIR grant for liver drug testing
Hepregen, maker of a system to test drugs used to treat liver toxicity, has brought in $500,000 in grant money from the National Science Foundation, according to Dow Jones VentureWire. Based in San Francisco, the company was previously backed by Battelle Ventures.
Next Story: Presto pulls $2M out of a hat to streamline semiconductor companies
Previous Story: OneRiot lures developers by sharing real-time ad revenue
About the Author, Camille Ricketts
Camille was the lead writer for GreenBeat until August 2010. To reach VentureBeat's current writers, email tips@venturebeat.com.
